Celularity Inc (CELU) Form 10-Q — Oct 20, 2026
Celularity's 10-Q discloses substantial doubt about its ability to continue as a going concern: cash fell to just $0.6 million from $6.2 million at year-end, with a $53.3 million working capital deficit and a $989.9 million accumulated deficit. The quarter showed GAAP net income of $0.7 million, but this was driven by one-time items — a $12.2 million New Jersey NOL sale, a $6.7 million legal settlement gain, offset by a $2.5 million Helena settlement loss. Six-month revenue fell 46% year-over-year to $9.3 million.
Key figures
- Eps
- 0.04
- Revenue
- 9278000
- Net Income
- 1580000
- Total Debt
- 8967000
- Total Assets
- 96167000
- Cash Position
- 586000
- Shares Outstanding
- 29283614
- Q2 2026 revenue
- 5432000
- Q2 2026 net income
- 706000
- Accumulated deficit
- 989903000
- Nj nol sale proceeds
- 12159000
- Working capital deficit
- 53290000
- Stock based compensation 6mo
- 2215000
- Subsequent private placement net
- 8800000
- Total recapitalization potential
- 25000000
- Subsequent private placement gross
- 9700000
AI analysis
Red flags9 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.